Literature DB >> 17095586

Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress.

Andrea M Vincent1, Lorena Perrone, Kelli A Sullivan, Carey Backus, Ann Marie Sastry, Christian Lastoskie, Eva L Feldman.   

Abstract

The receptor for advanced glycation end products (RAGE) may promote diabetic vascular and renal disease through the activation of intracellular signaling pathways that promote oxidative stress. Oxidative stress is a mediator of hyperglycemia-induced cell injury and a unifying theme for all mechanisms of diabetic complications, but there are few studies on the expression and potential contribution of RAGE in diabetic neuropathy. The current study demonstrates that dorsal root ganglia neurons express functional RAGE and respond to the RAGE ligand S100 with similar downstream signaling, oxidative stress, and cellular injury as other diabetic complication-prone tissues. RAGE-induced phosphatidylinositol-3 kinase activity is associated with formation of reactive oxygen species, caspase-3 activation, and nuclear DNA degradation. These events are prevented by treatment with the antioxidant alpha-lipoic acid. Our data indicate that therapies aimed at decreasing RAGE ligands, blocking RAGE signaling, or preventing oxidative stress could significantly decrease the development of neuropathy in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095586     DOI: 10.1210/en.2006-0073

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  92 in total

1.  Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy.

Authors:  M M Jack; J M Ryals; D E Wright
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

Review 2.  Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy.

Authors:  Megan Jack; Douglas Wright
Journal:  Transl Res       Date:  2012-01-10       Impact factor: 7.012

3.  Long-chain acyl coenzyme A synthetase 1 overexpression in primary cultured Schwann cells prevents long chain fatty acid-induced oxidative stress and mitochondrial dysfunction.

Authors:  Lucy M Hinder; Claudia Figueroa-Romero; Crystal Pacut; Yu Hong; Anuradha Vivekanandan-Giri; Subramaniam Pennathur; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2013-10-05       Impact factor: 8.401

4.  Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway.

Authors:  Mariarosa Anna Beatrice Melone; Clemente Dato; Simona Paladino; Cinzia Coppola; Claudia Trebini; Maria Teresa Giordana; Lorena Perrone
Journal:  Pharm Res       Date:  2018-02-05       Impact factor: 4.200

5.  Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy.

Authors:  Andrea M Vincent; James L Edwards; Lisa L McLean; Yu Hong; Federica Cerri; Ignazio Lopez; Angelo Quattrini; Eva L Feldman
Journal:  Acta Neuropathol       Date:  2010-05-15       Impact factor: 17.088

6.  Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons.

Authors:  Bhumsoo Kim; Lisa L McLean; Stephen S Philip; Eva L Feldman
Journal:  Endocrinology       Date:  2011-08-02       Impact factor: 4.736

Review 7.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

8.  Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms.

Authors:  Andrea M Vincent; Koichi Kato; Lisa L McLean; Mary E Soules; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

9.  Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Biomark Insights       Date:  2007-09-17

Review 10.  Exercise therapy in type 2 diabetes.

Authors:  Stephan F E Praet; Luc J C van Loon
Journal:  Acta Diabetol       Date:  2009-05-29       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.